Table 5. Overview of different published estimates of QALDs lost due to ILI, for sources which presented data or interpretation of that data.

Study	QALY weight Worst day/disease	Background QALY weight	Duration of disease (days)	QALD loss	Sample size	Method	Focus group	Age group
(Griffin, Perry, & Fleming, 2001)	−0.066	0.817	2.48	2.19*	21	EQ-5D	Patients (within 3 months after onset)	18+
(Griffin, Perry, & Fleming, 2001)	−0.263	0.72	2.48	2.45*	8	EQ-5D	GPs	Unknown
(O'Brien, Goeree, Blackhouse, Smieja, & Loeb, 2003)	Changed by day	Not reported	Not reported	Not reported	920 in placebo (639 with influenza	Likert score transferred to VAS	ILI patients (clinical trails antivirals GSK)	18–64
(Turner et al., 2003)	Changed by day	Not reported	Not reported	Not reported	See O'Brien at al	Converted the Likert scores into VAS scores converted those into time-trade off scores	ILI patients (clinical trails antivirals GSK)	18–64
(Rothberg, Bellantonio, & Rose, 2003)	0.25	1	Not reported	Not reported	15	HUI-3	Patients	Working adults
(Prosser et al., 2006)	Not reported	Not reported	Not reported	1.83	Not reported	Time trade off	Parents of children	Children
(Siddiqui & Edmunds, 2008)	VAS scores as presented by O'Brien et.al	0.85	Not reported	1.68 for influenza ILI1.57 for non-influenza ILI	See O'Brien et.al.	VAS scores substracted from the baseline	ILI patients	18–64
(Sander et al., 2010)	QALY scores as presented by Turner et.al.	Not reported	Not reported	5.33 (0–19 yrs)6.35 (20–64 yrs) 10.69 (65+)	See O'Brien et.al	Uses published QALY weights and combines this with unpublished disease duration	ILI patients	18–64